Adaptimmune Therapeutics (Adaptimmune Therapeutics) EPS without NRI : $-0.56 (TTM As of Dec. 2023)

Adaptimmune Therapeutics EPS without NRI Chart

Adaptimmune Therapeutics Annual Data
	Trend	Jun14	Jun15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EPS without NRI		Get a 7-Day Free Trial					-1.32	-0.90	-1.02	-1.01	-0.62

Adaptimmune Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS without NRI	Get a 7-Day Free Trial															-0.17	0.01	-0.22	-0.18	-0.18

Competitive Comparison of Adaptimmune Therapeutics's EPS without NRI

For the Biotechnology subindustry, Adaptimmune Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's PE Ratio without NRI falls into.

Adaptimmune Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics  (NAS:ADAP) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Adaptimmune Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description